TY - JOUR
T1 - Bridging the gap in the symptomatic heart failure patient journey
T2 - insights from the Italian scenario
AU - Ziacchi, Matteo
AU - Spadotto, Alberto
AU - Ghio, Stefano
AU - Pellegrino, Marta
AU - Potena, Luciano
AU - Masarone, Daniele
AU - Merlo, Marco
AU - Stolfo, Davide
AU - Caracciolo, Maria Michela
AU - Inserra, Corinna
AU - Ammirati, Fabrizio
AU - Ciccarelli, Michele
AU - Colivicchi, Furio
AU - Bianchi, Stefano
AU - Patti, Giuseppe
AU - Oliva, Fabrizio
AU - Arcidiacono, Giuseppe
AU - Rordorf, Roberto
AU - Pini, Daniela
AU - Pacileo, Giuseppe
AU - D’Onofrio, Antonio
AU - Forleo, Giovanni Battista
AU - Mariani, Matteo
AU - Adamo, Francesco
AU - Alonzo, Alessandro
AU - Ruzzolini, Matteo
AU - Ghiglieno, Chiara
AU - Cipriani, Manlio
AU - Firetto, Giorgio
AU - Aspromonte, Nadia
AU - Clemenza, Francesco
AU - Maria De Ferrari, Gaetano
AU - Senni, Michele
AU - Grazia Bongiorni, Maria
AU - Tondo, Claudio
AU - Grimaldi, Massimo
AU - Giallauria, Francesco
AU - Rametta, Francesco
AU - Marchese, Procolo
AU - Biffi, Mauro
AU - Sinagra, Gianfranco
N1 - Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Background: The prognosis for heart failure (HF) patients remains poor, with a high mortality rate, and a marked reduction in quality of life (QOL) and functional status. This study aims to explore the ongoing needs of HF management and the epidemiology of patients followed by Italian HF clinics, with a specific focus on cardiac contractility modulation (CCM). Research design and methods: Data from patients admitted to 14 HF outpatients clinics over 4 weeks were collected and compared to the results of a survey open to physicians involved in HF management operating in Italian centers. Results: One hundred and five physicians took part in the survey. Despite 94% of patients receive a regular follow-up every 3–6 months, available therapies are considered insufficient in 30% of cases. Physicians reported a lack of treatment options for 23% of symptomatic patients with reduced ejection fraction (EF) and for 66% of those without reduced EF. Approximately 3% of HF population (two patients per month per HF clinic) meets the criteria for immediate CCM treatment, which is considered a useful option by 15% of survey respondents. Conclusions: Despite this relatively small percentage, considering total HF population, CCM could potentially benefit numerous HF patients, particularly the elderly, by reducing hospitalizations, improving functional capacity and QOL.
AB - Background: The prognosis for heart failure (HF) patients remains poor, with a high mortality rate, and a marked reduction in quality of life (QOL) and functional status. This study aims to explore the ongoing needs of HF management and the epidemiology of patients followed by Italian HF clinics, with a specific focus on cardiac contractility modulation (CCM). Research design and methods: Data from patients admitted to 14 HF outpatients clinics over 4 weeks were collected and compared to the results of a survey open to physicians involved in HF management operating in Italian centers. Results: One hundred and five physicians took part in the survey. Despite 94% of patients receive a regular follow-up every 3–6 months, available therapies are considered insufficient in 30% of cases. Physicians reported a lack of treatment options for 23% of symptomatic patients with reduced ejection fraction (EF) and for 66% of those without reduced EF. Approximately 3% of HF population (two patients per month per HF clinic) meets the criteria for immediate CCM treatment, which is considered a useful option by 15% of survey respondents. Conclusions: Despite this relatively small percentage, considering total HF population, CCM could potentially benefit numerous HF patients, particularly the elderly, by reducing hospitalizations, improving functional capacity and QOL.
KW - Heart failure
KW - cardiac contractility modulation
KW - device therapy
KW - personalized medicine
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85171522339&partnerID=8YFLogxK
U2 - 10.1080/17434440.2023.2258786
DO - 10.1080/17434440.2023.2258786
M3 - Article
SN - 1743-4440
VL - 20
SP - 951
EP - 961
JO - Expert Review of Medical Devices
JF - Expert Review of Medical Devices
IS - 11
ER -